Epigral Ltd (EPIGRAL) is currently trading at 1,146.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Epigral Limited, formerly Meghmani Finechem Limited, is a prominent player in India's chlor alkali industry, involved in manufacturing chlor alkali products and derivatives, along with trading agrochemicals. The company has recently finalized capex plans aiming to double the capacity of its CPVC and epichlorohydrin plants, hinting at a robust strategic expansion. Revenue increased modestly by 2% in Q3 FY26, driven by volume growth despite challenging market conditions due to geopolitical uncertainties and a prolonged monsoon season. Epigral reported an EBITDA margin contraction to 17% due to lower product realizations and rising raw material costs, although sustained 9-month margins were at 22%. Forward integration efforts continue with commission of India's first Chlorotoluenes Value Chain Facility and plans for an upcoming pilot plant, reflecting a focus on expanding vertically and improving manufacturing capabilities.

Over the past 52 weeks, Epigral Ltd has traded between a low of ₹806.20 and a high of ₹1,807.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Epigral Ltd has a market capitalization of approximately 5,012.16. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Epigral Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.49 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5,012.16 Cr, Epigral Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Epigral Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Epigral Ltd is 18.49. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Epigral reported standalone net profit (PAT) of ₹99.18 crore for the quarter ended June 30, 2026.

The filing shows revenue from operations of ₹705.36 crore (total income ₹709.46 crore) and standalone PAT of ₹99.18 crore for the quarter ended June 30, 2026; consolidated PAT was ₹99.74 crore.

Epigral reported revenue from operations of ₹709 crore and PAT of ₹99 crore for the quarter ended June 30, 2026.

The stock jumped after PAT more than doubled sequentially to Rs 81.93 crore and EBITDA margin improved to 23% from 17% in Q3 FY26, alongside record quarterly revenue.